New hope for bile duct cancer: experimental drug combo enters final testing
NCT ID NCT06591520
First seen Jan 22, 2026 · Last updated May 16, 2026 · Updated 18 times
Summary
This study tests whether a new drug called AK112, when combined with standard chemotherapy, works better than another drug (durvalumab) plus the same chemo for people with advanced bile duct cancer that cannot be removed by surgery. About 682 adults with good overall health will take part. The main goal is to see if the new combination helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harbin Medical University Cancer Hospital
Harbin, China
-
Zhongshan Hospital, Fudan University
Shanghai, China
Conditions
Explore the condition pages connected to this study.